| PATENT ASSIGNEE'S COUNTRY | USA |
| UPDATE | 12.00 |
| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 12.12.00 |
| PATENT TITLE |
Pyrazinones and triazinones and their derivatives thereof |
| PATENT ABSTRACT |
Corticotropin releasing factor (CRF) antagonists of Formula (I) ##STR1## and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | 15.09.97 |
| PATENT REFERENCES CITED |
Appleton et al, Chemical Abstracts, vol. 93 entry 114569 (1980). H. Neunhoeffer, 1,2,4-Triazines and the Benzo Derivatives, Comprehensive Heterocyclic Chemistry, Katritsky & Rees, ed, vol. 3, pp. 385-456, 1984. Nakamura et al., Agric. Biol. Chem., 47 (7), 1561-1567, 1983. |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
We claim: 1. A compound of Formula I: ##STR14## or a pharmaceutically acceptable salt form thereof, wherein: Z is CR.sup.2 ; Y is NR.sup.4, O, S(O).sub.n ; Ar is phenyl, naphthyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, indolinyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, benzothiazolyl, indazolyl, isoxazolyl or pyrazolyl, each substituted with 0 to 4 R.sup.5 groups; wherein Ar is attached to Y through an unsaturated carbon; R.sup.1 is H, halo, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --OR.sup.7, --SH, --S(O).sub.n R.sup.13, --COR.sup.7, --CONR.sup.6 R.sup.7, --CO.sub.2 R.sup.7, --OC(O)R.sup.13, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, or --NR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.7, --SH, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --OC(O)R.sup.13, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, aryl and heterocyclyl; R.sup.2 is H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, halo, --CN, C.sub.1 -C.sub.4 haloalkyl, --NR.sup.9 R.sup.10, --NR.sup.9 COR.sup.10, --NR.sup.9 CO.sub.2 R.sup.10, --OR.sup.11, --SH or --S(O).sub.n R.sup.12 ; R.sup.3 is C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --OR.sup.7, --S(O).sub.2 R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, or --NR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, aryl and heterocyclyl, with the proviso that when R.sup.3 is aryl, Ar is not imidazolyl; R.sup.4 is H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl, wherein C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl is optionally substituted with C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl and wherein C.sub.1 -C.sub.6 alkyl is optionally substituted with C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, --S(O).sub.n R.sup.12, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 or --NR.sup.9 COR.sup.10 ; R.sup.5 is independently selected at each occurrence from C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, heterocyclyl, --NO.sub.2, halo, --CN, C.sub.1 -C.sub.4 haloalkyl, --NR.sup.6 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --OR.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7, --CONR.sup.6 R.sup.7, --CON(OR.sup.9)R.sup.7, --SH, and --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, --NO.sub.2, halo, --CN, --OR.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7, --CONR.sup.6 R.sup.7, --NR.sup.6 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CO.sub..sub.2 R.sup.7 and --S(O).sub.n R.sup.13 ; R.sup.6 and R.sup.7 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl, heterocyclyl(C.sub.1 -C.sub.4 alkyl)-, morpholinoethyl, morpholinopropyl and morpholinobutyl; or NR.sup.6 R.sup.7 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine; wherein C.sub.1 -C.sub.4 alkyl, may be substituted with 0 to 2 substituents independently selected at each occurrence from --OH or C.sub.1 -C.sub.4 alkoxy groups; R.sup.8 is independently at each occurrence H or C.sub.1 -C.sub.4 alkyl; R.sup.9 and R.sup.10 are independently at each occurrence selected from H, C.sub.1 -C.sub.4 alkyl and C.sub.3 -C.sub.6 cycloalkyl; R.sup.11 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl; R.sup.12 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl or --NR.sup.6 R.sup.7 ; R.sup.13 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.6 R.sup.7, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl)-; R.sup.14 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl; or --NR.sup.15 R.sup.16 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methyl-piperazine, morpholine or thiomorpholine; aryl is phenyl, biphenyl or naphthyl, each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.15, --SH, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --OC(O)R.sup.14, --NO.sub.2, --NR.sup.8 COR.sup.15, --N(COR.sup.l5).sub.2, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15, --NR.sup.15 R.sup.16 and --CONR.sup.15 R.sup.16 ; heterocyclyl is pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzthiazolyl, isoxazolyl or pyrazolyl, each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.15, --SH, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --OC(O)R.sup.14, --NO.sub.2, --NR.sup.8 COR.sup.15, --N(COR.sup.15).sub.2, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15, --NR.sup.15 R.sup.16 and --CONR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. 2. A compound of claim 1 wherein: Z is CR.sup.2 ; Y is NR.sup.4 or O; Ar is phenyl or pyridyl, each substituted with 0 to 4 R.sup.5 groups; R.sup.1 is H, halo, C.sub.1 -C.sub.4 alkyl, cyclopropyl, C.sub.1 -C.sub.4 haloalkyl, --CN, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --OR.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7 or --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.4 alkyl is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 and aryl; R.sup.2 is H, C.sub.1 -C.sub.4 alkyl, halo, C.sub.1 -C.sub.4 haloalkyl; R.sup.3 is C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --OR.sup.7, --S(O).sub.2 R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, or --NR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, aryl and heterocyclyl; R.sup.4 is H, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkenyl, wherein C.sub.1 -C.sub.6 alkyl is optionally substituted with C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, --S(O).sub.n R.sup.12, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 or --NR.sup.9 COR.sup.10 ; R.sup.5 is independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.8 cycloalkylalkyl, aryl, heterocyclyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --NO.sub.2, --NR.sup.6 R.sup.7, --COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, --CON (OR.sup.9) R.sup.7, CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.8 cycloalkylalkyl are substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, --NO.sub.2, halo, --CN, --NR.sup.6 R.sup.7, COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13 ; R.sup.6 and R.sup.7 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl, heterocyclyl(C.sub.1 -C.sub.4 alkyl)-, morpholinoethyl, morpholinopropyl and morpholinobutyl; or --NR.sup.6 R.sup.7 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine; wherein C.sub.1 -C.sub.4 alkyl, may be substituted with 0 to 2 substituents independently selected at each occurrence from --OH or C.sub.1 -C.sub.4 alkoxy groups; R.sup.8 is independently at each occurrence H or C.sub.1 -C.sub.4 alkyl; R.sup.9 and R.sup.10 are independently at each occurrence selected from H, C.sub.1 -C.sub.4 alkyl and C.sub.3 -C.sub.6 cycloalkyl; R.sup.11 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl; R.sup.12 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl or --NR.sup.6 R.sup.7 ; R.sup.13 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.6 R.sup.7, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl)-; R.sup.14 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl; or --NR.sup.15 R.sup.16 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methyl-piperazine, morpholine or thiomorpholine; aryl is phenyl substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --NO.sub.2, --NR.sup.8 COR.sup.15, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15 and --NR.sup.15 R.sup.16 ; heterocyclyl is pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl or pyrazolyl, each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --CO.sub.2 R.sup.15, --NO.sub.2, --NR.sup.8 COR.sup.15, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15, and --NR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. 3. A compound of claim 2 wherein: Z is CR.sup.2 ; Y is NR.sup.4 ; Ar is phenyl or pyridyl, each substituted with 0 to 4 R.sup.5 groups; R.sup.1 is H, halo, C.sub.1 -C.sub.4 alkyl, cyclopropyl, C.sub.1 -C.sub.3 haloalkyl, --CN, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7, --OR.sup.7 or --S(O).sub.n R.sup.13 wherein C.sub.1 -C.sub.4 alkyl is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.3 -C.sub.4 cycloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 ; R.sup.2 is H; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl or aryl, wherein C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or C.sub.3 -C.sub.6 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 and aryl; R.sup.4 is H, allyl, or C.sub.1 -C.sub.4 alkyl, wherein C.sub.1 -C.sub.4 alkyl is optionally substituted with C.sub.1 -C.sub.4 alkyl, --OR.sup.7, --S(O).sub.2 R.sup.12, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 or --NR.sup.9 COR.sup.10 ; R.sup.5 is independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, aryl, heterocyclyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --NO.sub.2, --NR.sup.6 R.sup.7, --COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, --CON(OR.sup.9)R.sup.7, --CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.6 alkyl is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, --NO.sub.2, halo, --CN, --NR.sup.6 R.sup.7, COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13 ; R.sup.6 and R.sup.7 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl and C.sub.2 -C.sub.8 alkoxyalkyl; wherein C.sub.1 -C.sub.4 alkyl, may be substituted with 0 to 2 substituents independently selected at each occurrence from --OH or C.sub.1 -C.sub.4 alkoxy groups; R.sup.8, R.sup.9 and R.sup.10 are independently at each occurrence H or C.sub.1 -C.sub.4 alkyl; R.sup.12 and R.sup.13 are independently at each occurrence C.sub.1 -C.sub.4 alkyl or --NR.sup.6 R.sup.7 ; R.sup.14 is C.sub.1 -C.sub.4 alkyl or --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently at each occurrence H, C.sub.1 -C.sub.4 alkyl or C.sub.2 -C.sub.8 alkoxyalkyl; aryl is phenyl substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, S(O).sub.n R.sup.14, --COR.sup.15 --CO.sub.2 R.sup.15, --NO.sub.2 and --NR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. 4. A compound of claim 3 wherein: Z is CR.sup.2 ; Y is NR.sup.4 ; Ar is phenyl or pyridyl, each substituted with 2 to 4 R.sup.5 groups; R.sup.1 is H, Cl, Br, methyl, ethyl, cyclopropyl, or --CN, R.sup.2 is H; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl or aryl, wherein C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or C.sub.3 -C.sub.6 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, --CF.sub.3, halo, --CN, --OR.sup.7, and aryl; R.sup.4 is H, methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, n-butyl, or allyl; R.sup.5 is independently selected at each occurrence from methyl, ethyl, i-propyl, n-propyl, aryl, --CF.sub.3, halo, --CN, --N(CH.sub.3)2, --C(.dbd.O)CH.sub.3, --OCH.sub.3, --OCH.sub.2 CH.sub.3, --OCF.sub.3, and --S(O).sub.2 CH.sub.3 ; R.sup.14 is C.sub.1 -C.sub.4 alkyl or --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently at each occurrence H, C.sub.1 -C.sub.4 alkyl or C.sub.2 -C.sub.8 alkoxyalkyl; aryl is phenyl substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sub.5, --NO.sub.2 and --NR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. 5. A compound of claim 4 selected from: 3-[(2,4-Dibromophenyl)amino]-5-chloro-1-(1-ethylpropyl)-2(1H)-pyrazinone; 3-[[2-Bromo-4-(1-methylethyl)phenyl]amino]-5-chloro-1-(1-ethylpropyl)-2(1H) -pyrazinone; 3-[(2,4-Dibromophenyl)ethylamino]-5-chloro-1-(1-ethylpropyl)-2(1H)-pyrazino ne; 3-[[2-Bromo-4-(1-methylethyl)phenyl]ethylamino]-5-chloro-1-(1-ethylpropyl)- 2(1H)-pyrazinone; 3-[(2,4,6-Trimethylphenyl)amino]-5-chloro-1-(1-ethylpropyl)-2(1H)-pyrazinon e; 3-[(2,4,6-Trimethylphenyl)ethylamino]-5-chloro-1-(1-ethylpropyl)-2(1H)-pyra zinone; (+/-)-3-[(2,4,6-Trimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)propyl] -2 (1H)-pyrazinone; 3-[(2-Bromo-4,6-dimethoxyphenyl)amino]-5-chloro-1-(1-ethylpropyl)-2(1H)-pyr azinone; 3-[(2-Cyano-4,6-dimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)propyl]- 2 (1H)-pyrazinone; (+/-)-3-[(2-Bromo-4,6-dimethoxyphenyl)amino]-5-chloro-1-[1-(methoxymethyl)p ropyl]-2 (1H)-pyrazinone; (+/-)-3-[(2-chloro-4,6-dimethoxyphenyl)amino]-5-chloro-1-[1-(methoxymethyl) propyl]-2 (1H)-pyrazinone; (+/-)-3-[(4,6-Dimethyl-2-iodophenyl)amino]-5-chloro-1-[1-(methoxymethyl)pro pyl]-2 (1H)-pyrazinone; [(2-cyano-4,6-dimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)propyl]-2( 1H)-pyrazinone; (+/-)-3-[(2-Bromo-4,6-dimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)pr opyl]-2 (1H)-pyrazinone; (+/-)-3-[(4-Bromo-2,6-dimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)pr opyl]-2(1H)-pyrazinone; (+/-)-3-[(4-Acetyl-2,6-dimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)p ropyl]-2 (1H)-pyrazinone; (+/-)-3-[(2-Acetyl-4,6-dimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)p ropyl]-2(1H)-pyrazinone; (+/-)-3-[(4,6-Dimethyl-2-thiomethylphenyl)amino]-5-chloro-1-[1-(methoxymeth yl)propyl]-2(1H)-pyrazinone; (+/-)-3-[(4,6-Dimethyl-2-methylsulfonylphenyl)amino]-5-chloro-1-[1-(methoxy methyl)propyl]-2(1H)-pyrazinone; (+/-)-3-[(4-chloro-2-iodo-6-methylphenyl)amino]-5-chloro-1-[1-(methoxymethy l)propyl]-2(1H)-pyrazinone; 3-[(2,4,6-Trimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)-2-methoxyeth yl]-2(1H)-pyrazinone; 3-[(2,4,6-Trimethylphenyl)amino]-5-chloro-1-phenyl-2(1H)-pyrazinone; (+/-)-3-[(2,4-Dibromophenyl)amino]-5-methyl-1-[1-(methoxymethyl)propyl]-2(1 H)-pyrazinone; (+/-)-3-[[2-Bromo-4-(1-methylethyl)phenyl]amino]-5-methyl-1-[1-(methoxymeth yl)propyl]-2(1H)-pyrazinone; (+/-)-3-[(2,4,6-Trimethylphenyl)amino]-5-methyl-1-[1-(methoxymethyl)propyl] -2(1H)-pyrazinone; 3-[(2,4,6-Trimethylphenyl)amino]-5-methyl-1-[1-(methoxymethyl)-2-methoxyeth yl]-2(1H)-pyrazinone; 3-[(2,4-Dichloro-6-methylphenyl)amino]-5-methyl-1-[1-(methoxymethyl)-2-meth oxyethyl]-2(1H)-pyrazinone; 3-[(2,4-Dichloro-6-methylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)-2-meth oxyethyl]-2(1H)-pyrazinone; 3-[(2,4-Dibromo-6-methylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)-2-metho xyethyl]-2(1H)-pyrazinone; (+/-)-3-[(2,4,6-Trimethylphenyl)amino]-5-methyl-1-[1-(methoxymethyl)-3-meth oxypropyl]-2(1H)-pyrazinone; (+/-)-3-[(2,4,6-Trimethylphenyl)amino]-5-chloro-1-[1-(methoxymethyl)-3-meth oxypropyl]-2(1H)-pyrazinone; 3-[(2,4,6-Trimethylphenyl)amino]-5-chloro-1-[1-(2-methoxyethyl)-3-methoxypr opyl]-2(1H)-pyrazinone; (+/-)-3-[(2,4-Dimethyl-6-methoxyphenyl)amino]-5-chloro-1-[1-(methoxymethyl) propyl]-2(1H)-pyrazinone; (+/-)-3-[(2,4-Dimethyl-6-methoxyphenyl)amino]-5-chloro-1-[1-(methoxymethyl) -3-methoxypropyl]-2(1H)-pyrazinone; (+/-)-3-[(2,4-Dimethyl-6-methoxyphenyl)amino]-5-methyl-1-[1-(methoxymethyl) -3-methoxypropyl]-2(1H)-pyrazinone; (+/-)-3-[(4-Bromo-2,6-dimethylphenyl)amino]-5-methyl-1-[1-(methoxymethyl)-3 -methoxypropyl]-2(1H)-pyrazinone; (+/-)-3-[(2-chloro-4,6-dimethylphenyl)amino]-5-methyl-1-[1-(methoxymethyl)- 3-methoxypropyl]-2(1H)-pyrazinone; (+/-)-3-[[2,4-Dimethyl-6-(methoxymethyl)phenyl]amino]-5-methyl-1-[1-(methox ymethyl)-3-methoxypropyl]-2(1H)-pyrazinone; |
| PATENT DESCRIPTION |
FIELD OF THE INVENTION This invention relates to novel compounds and pharmaceutical compositions, and to methods of using same in the treatment of psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders. BACKGROUND OF THE INVENTION Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin(POMC)-derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983); G. F. Koob, Persp. Behav. Med. 2:39 (1985); E. B. De Souza et al., J. Neurosci. 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J. E. Blalock, Physiological Reviews 69:1 (1989); J. E. Morley, Life Sci. 41:527 (1987)]. Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and eating disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E. B. De Souza, Hosp. Practice 23:59 (1988)]. In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C. B. Nemeroff et al., Science 226:1342 (1984); C. M. Banki et al., Am. J. Psychiatry 144:873 (1987); R. D. France et al., Biol. Psychiatry 28:86 (1988); M. Arato et al., Biol Psychiatry 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C. B. Nemeroff et al., Arch. Gen. Psychiatry 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P. W. Gold et al., Am J. Psychiatry 141:619 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P. W. Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R. M. Sapolsky, Arch. Gen. Psychiatry 46:1047 (1989)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al., Neuropsychopharmacology 2:53 (1989)]. There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine/non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D. R. Britton et al., Life Sci. 31:363 (1982); C. W. Berridge and A. J. Dunn Regul. Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist a-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C. W. Berridge and A. J. Dunn Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990)]. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K. T. Britton et al., Psychopharmacology 86:170 (1985); K. T. Britton et al., Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N. R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Ro15-1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K. T. Britton et al., Psychopharmacology 94:306 (1988)]. The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (a-helical CRF.sub.9-41) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G. F. Koob and K. T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E. B. De Souza and C. B. Nemeroff eds., CRC Press p221 (1990)]. DuPont Merck PCT application WO95/10506 describes corticotropin releasing factor antagonist compounds and their use to treat psychiatric disorders and neurological diseases. European patent application 0 576 350 A1 by Elf Sanofi describes corticotropin releasing factor antagonist compounds useful in the treatment of CNS and stress disorders. Pfizer patent applications WO 94/13676, WO 94/13677, WO 94/13661, WO 95/33750, WO 95/34563, WO 95/33727 describe corticotropin releasing factor antagonist compounds useful in the treatment of CNS and stress disorders. All of the aforementioned references are hereby incorporated by reference. The compounds and the methods of the present invention provide for the production of compounds capable of inhibiting the action of CRF at its receptor protein in the brain. These compounds would be useful in the treatment of a variety of neurodegenerative, neuropsychiatric and stress-related disorders such as affective disorders, anxiety, depression, post-traumatic stress disorders, supranuclear palsy, seizure disorders, stroke, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal disease, anorexia nervosa or other eating disorders, drug or alcohol withdrawal symptoms, drug addiction, inflammatory disorders and fertility problems. It is further asserted that this invention may provide compounds and pharmaceutical compositions suitable for use in such a method. SUMMARY OF THE INVENTION This invention is a class of novel compounds which are CRF receptor antagonists and which can be represented by Formula (I): ##STR2## or a pharmaceutically acceptable salt form thereof, wherein Z is CR.sup.2 or N; when Z is CR.sup.2 : Y is NR.sup.4, O or S(O).sub.n ; Ar is phenyl, naphthyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, indolinyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, benzothiazolyl, indazolyl, isoxazolyl or pyrazolyl, each substituted with 0 to 4 R.sup.5 groups; wherein Ar is attached to Y through an unsaturated carbon; R.sup.1 is H, halo, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --OR.sup.7, --SH, --S(O).sub.n R.sup.13, --COR.sup.7, --CONR.sup.6 R.sup.7, --CO.sub.2 R.sup.7, --OC(O)R.sup.13, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, or --NR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.7, --SH, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --OC(O)R.sup.13, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, aryl and heterocyclyl; R.sup.2 is H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, halo, --CN, C.sub.1 -C.sub.4 haloalkyl, --NR.sup.9 R.sup.10, --NR.sup.9 COR.sup.10, --NR.sup.9 CO.sub.2 R.sup.10, --OR.sup.11, --SH or --S(O).sub.n R.sup.12 ; R.sup.3 is C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --OR.sup.7, --S(O).sub.2 R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, or --NR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, aryl and heterocyclyl, with the proviso that when R.sup.3 is aryl, Ar is not imidazolyl; R.sup.4 is H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl, wherein C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl is optionally substituted with C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl and wherein C.sub.1 -C.sub.6 alkyl is optionally substituted with C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, --S(O).sub.n R.sup.12, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 or --NR.sup.9 COR.sup.10 ; R.sup.5 is independently selected at each occurrence from C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, heterocyclyl, --NO.sub.2, halo, --CN, C.sub.1 -C.sub.4 haloalkyl, --NR.sup.6 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --OR.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7, --CONR.sup.6 R.sup.7, --CON(OR.sup.9)R.sup.7, --SH, and --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, --NO.sub.2, halo, --CN, --OR.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7, --CONR.sup.6 R.sup.7, --NR.sup.6 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13 ; R.sup.6 and R.sup.7 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl, heterocyclyl(C.sub.1 -C.sub.4 alkyl)-, morpholinoethyl, morpholinopropyl and morpholinobutyl; or --NR.sup.6 R.sup.7 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methyl-piperazine, morpholine or thiomorpholine; wherein C.sub.1 -C.sub.4 alkyl, may be substituted with 0 to 2 substituents independently selected at each occurrence from --OH or C.sub.1 -C.sub.4 alkoxy groups; R.sup.8 is independently at each occurrence H or C.sub.1 -C.sub.4 alkyl; R.sup.9 and R.sup.10 are independently at each occurrence selected from H, C.sub.1 -C.sub.4 alkyl and C.sub.3 -C.sub.6 cycloalkyl; R.sup.11 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl; R.sup.12 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl or --NR.sup.6 R.sup.7 ; R.sup.13 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.6 R.sup.7, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl)-; R.sup.14 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl; or --NR.sup.15 R.sup.16 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methyl-piperazine, morpholine or thiomorpholine; aryl is phenyl, biphenyl or naphthyl, each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.15, --SH, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --OC(O)R.sup.14, --NO.sub.2, --NR.sup.8 COR.sup.15, --N(COR.sup.15).sub.2, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15, --NR.sup.15 R.sup.16 and --CONR.sup.15 R.sup.16 ; heterocyclyl is 5- to 10-membered heterocyclic ring which may be saturated, partially unsaturated or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S, wherein the heterocyclic ring is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.15, --SH, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --OC(O)R.sup.14, --NR.sup.8 COR.sup.15, --N(COR.sup.15).sub.2, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15, --NR.sup.15 R.sup.16, and --CONR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2; and wherein, when Z is N: Y is NR.sup.4, O or S(O).sub.n ; Ar, R.sup.1, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, aryl, heterocyclyl, heterocyclyl and n are as defined above, but R.sup.3 is C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --S(O).sub.2 R.sup.13, --CO.sub.2 R.sup.7, --COR.sup.7 or --CONR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, aryl and heterocyclyl, with the proviso that when R.sup.3 is aryl, Ar is not imidazolyl. [3] Preferred compounds of this invention are compounds of Formula (I) and pharmaceutically acceptable salts and pro-drug forms thereof, wherein: Z is CR.sup.2 ; Y is NR.sup.4 or O; Ar is phenyl or pyridyl, each substituted with 0 to 4 R.sup.5 groups; R.sup.1 is H, halo, C.sub.1 -C.sub.4 alkyl, cyclopropyl, C.sub.1 -C.sub.4 haloalkyl, --CN, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --OR.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7 or --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.4 alkyl is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 and aryl; R.sup.2 is H, C.sub.1 -C.sub.4 alkyl, halo, C.sub.1 -C.sub.4 haloalkyl; R.sup.3 is C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, heterocyclyl, --CN, --OR.sup.7, --S(O).sub.2 R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, or --NR.sup.6 R.sup.7, wherein C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl or C.sub.3 -C.sub.8 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.l3, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7, aryl and heterocyclyl; R.sup.4 is H, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkenyl, wherein C.sub.1 -C.sub.6 alkyl is optionally substituted with C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, --S(O).sub.n R.sup.12, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 or --NR.sup.9 COR.sup.10 ; R.sup.5 is independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.8 cycloalkylalkyl, aryl, heterocyclyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --NO.sub.2, --NR.sup.6 R.sup.7, --COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, --CON(OR.sup.9)R.sup.7, CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.8 cycloalkylalkyl are substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, --NO.sub.2, halo, --CN, --NR.sup.6 R.sup.7, COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13 ; R.sup.6 and R.sup.7 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl, heterocyclyl(C.sub.1 -C.sub.4 alkyl)-, morpholinoethyl, morpholinopropyl and morpholinobutyl; or --NR.sup.6 R.sup.7 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine; wherein C.sub.1 -C.sub.4 alkyl, may be substituted with 0 to 2 substituents independently selected at each occurrence from --OH or C.sub.1 -C.sub.4 alkoxy groups; R.sup.8 is independently at each occurrence H or C.sub.1 -C.sub.4 alkyl; R.sup.9 and R.sup.10 are independently at each occurrence selected from H, C.sub.1 -C.sub.4 alkyl and C.sub.3 -C.sub.6 cycloalkyl; R.sup.11 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl; R.sup.12 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl or --NR.sup.6 R.sup.7 ; R.sup.13 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.6 R.sup.7, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl)-; R.sup.14 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl; or --NR.sup.15 R.sup.16 taken together as a whole is piperidine, pyrrolidine, piperazine, N-methyl-piperazine, morpholine or thiomorpholine; aryl is phenyl substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --NO.sub.2, --NR.sup.8 COR.sup.15, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15 and --NR.sup.15 R.sup.16 ; heterocyclyl is pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl or pyrazolyl, each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --CO.sub.2 R.sup.15, --NO.sub.2, --NR.sup.8 COR.sup.15, --NR.sup.8 CONR.sup.15 R.sup.16, --NR.sup.8 CO.sub.2 R.sup.15, and --NR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. [4] More preferred compounds of this invention are compounds of Formula (I) and pharmaceutically acceptable salts and pro-drug forms thereof, wherein: Z is CR.sup.2 ; Y is NR.sup.4 ; Ar is phenyl or pyridyl, each substituted with 0 to 4 R.sup.5 groups; R.sup.1 is H, halo, C.sub.1 -C.sub.4 alkyl, cyclopropyl, C.sub.1 -C.sub.3 haloalkyl, --CN, --NR.sup.6 R.sup.7, --CONR.sup.6 R.sup.7, --COR.sup.7, --CO.sub.2 R.sup.7, --OR.sup.7 or --S(O).sub.n R.sup.13 wherein C.sub.1 -C.sub.4 alkyl is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.3 -C.sub.4 cycloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --COR.sup.7, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 ; R.sup.2 is H; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl or aryl, wherein C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or C.sub.3 -C.sub.6 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --OR.sup.7, --S(O).sub.n R.sup.13, --CO.sub.2 R.sup.7, --NR.sup.8 COR.sup.7, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 and aryl; R.sup.4 is H, allyl, or C.sub.1 -C.sub.4 alkyl, wherein C.sub.1 -C.sub.4 alkyl is optionally substituted with C.sub.1 -C.sub.4 alkyl, --OR.sup.7, --S(O).sub.2 R.sup.12, --CO.sub.2 R.sup.7, --NR.sup.6 R.sup.7 or --NR.sup.9 COR.sup.10 ; R.sup.5 is independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, aryl, heterocyclyl, C.sub.1 -C.sub.4 haloalkyl, halo, --CN, --NO.sub.2, --NR.sup.6 R.sup.7, --COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, --CON(OR.sup.9)R.sup.7, --CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13, wherein C.sub.1 -C.sub.6 alkyl is substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, --NO.sub.2, halo, --CN, --NR.sup.6 R.sup.7, COR.sup.7, --OR.sup.7, --CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7 and --S(O).sub.n R.sup.13 ; R.sup.6 and R.sup.7 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl and C.sub.2 -C.sub.8 alkoxyalkyl; wherein C.sub.1 -C.sub.4 alkyl, may be substituted with 0 to 2 substituents independently selected at each occurrence from --OH or C.sub.1 -C.sub.4 alkoxy groups; R.sup.8, R.sup.9 and R.sup.10 are independently at each occurrence H or C.sub.1 -C.sub.4 alkyl; R.sup.12 and R.sup.13 are independently at each occurrence C.sub.1 -C.sub.4 alkyl or --NR.sup.6 R.sup.7 ; R.sup.14 is C.sub.1 -C.sub.4 alkyl or --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently at each occurrence H, C.sub.1 -C.sub.4 alkyl or C.sub.2 -C.sub.8 alkoxyalkyl; aryl is phenyl substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --NO.sub.2 and --NR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. [5] Even more preferred compounds of this invention are compounds of Formula (I) and pharmaceutically acceptable salts and pro-drug forms thereof, wherein: Z is CR.sup.2 ; Y is NR.sup.4 ; Ar is phenyl or pyridyl, each substituted with 2 to 4 R.sup.5 groups; R.sup.1 is H, Cl, Br, methyl, ethyl, cyclopropyl, or --CN, R.sup.2 is H; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 haloalkyl or aryl, wherein C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or C.sub.3 -C.sub.6 cycloalkyl is each substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, --CF.sub.3, halo, --CN, --OR.sup.7, and aryl; R.sup.4 is H, methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, n-butyl, or allyl; R.sup.5 is independently selected at each occurrence from methyl, ethyl, i-propyl, n-propyl, aryl, --CF.sub.3, halo, --CN, --N(CH.sub.3).sub.2, --C(.dbd.O)CH.sub.3, --OCH.sub.3, --OCH.sub.2 CH.sub.3, --OCF.sub.3, and --S(O).sub.2 CH.sub.3 ; R.sup.14 is C.sub.1 -C.sub.4 alkyl or --NR.sup.15 R.sup.16 ; R.sup.15 and R.sup.16 are independently at each occurrence H, C.sub.1 -C.sub.4 alkyl or C.sub.2 -C.sub.8 alkoxyalkyl; aryl is phenyl substituted with 0 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, halo, --CN, --OR.sup.15, --S(O).sub.n R.sup.14, --COR.sup.15, --CO.sub.2 R.sup.15, --NO.sub.2 and --NR.sup.15 R.sup.16 ; and n is independently at each occurrence 0, 1 or 2. [6] Specifically preferred compounds of this invention are compounds of Formula (I), pharmaceutically acceptable salts and pro-drug forms thereof, which are: 3-[(2,4-Dibromophenyl)amino]-5-chloro-1-(1-ethylpropyl)-2(1H)-pyrazinone; 3-[[2-Bromo-4-(1-methylethyl)phenyl]amino]-5-Chloro-1-(1-ethylpropyl)-2(1H) -pyrazinone; 3-[(2,4-Dibromophenyl)ethylamino]-5-Chloro-1-(1-ethylpropyl)-2(1H)-pyrazino ne; 3-[[2-Bromo-4-(1-methylethyl)phenyl]ethylamino]-5-chloro-1-(1-ethylpropyl)- 2(1H)-pyrazinone; 3-[(2,4,6-Trimethylphenyl)amino]-5-Chloro-1-(1-ethylpropyl)-2(1H)-pyrazinon e; 3-[(2,4,6-Trimethylphenyl)ethylamino]-5-Chloro-1-(1-ethylpropyl)-2(1H)-pyra zinone; (+/-)-3-[(2,4,6-Trimethylphenyl)amino]-5-Chloro-1-[1-(methoxymethyl)propyl] -2(1H)-pyrazinone; 3-[(2-Bromo-4,6-dimethoxyphenyl)amino]-5-Chloro-1-(1-ethylpropyl)-2(1H)-pyr azinone; 3-[(2-Cyano-4,6-dimethylphenyl)amino]-5-Chloro-1-[1-(methoxymethyl)propyl]- 2(1H)-pyrazinone; (+/-)-3-[(2-Bromo-4,6-dimethoxyphenyl)amino]-5-Chloro-1-[1-(methoxymethyl)p ropyl]-2(1H)-pyrazinone; (+/-)-3-[(2-Chloro-4,6-dimethoxyphenyl)amino]-5-Chloro-1-[1-(methoxymethyl) propyl]-2 (1H)-pyrazinone; (+/-)-3-[(4,6-Dimethyl-2-iodophenyl)amino]-5-Chloro-1-[1-(methoxymethyl)pro pyl]-2(1H)-pyrazinone; 3-[(2-Cyano-4,6-dimethylphenyl)amino]-5-Chloro-1-[1-(methoxymethyl)propyl]- 2(1H)-pyrazinone; |
| PATENT EXAMPLES | This data is not available for free |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |